QUELIMMUNE (SCD-PED) PediAtric SurVeillance REgistry

Recruiting now

Conditions studied: Acute Kidney Injury, Acute Kidney Injury Due to Sepsis

In brief

QUELIMMUNE is FDA-approved under an HDE for the treatment of pediatric patients (weight ≥10kg and age ≤22 years) with AKI due to sepsis or a septic condition on antibiotic therapy and requiring RRT. The purpose of this surveillance registry is to prospectively collect safety data among all patients treated with QUELIMMUNE under the HDE. More specifically, we intend on comparing the incidence of new (secondary) blood stream infections in the first 28 days after SCD-PED initiation to a comparator group of matched CKRT patients with sepsis who did not receive treatment with QUELIMMUNE

Key facts

Study ID
NCT06517810
Run by
SeaStar Medical
People needed
50
Starts
2024-07-19
Expected to finish
2026-08-01
Last updated by the study team
2026-05-14

Who can join

Age: any, up to 22. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.